Table 1.
Main clinical features of the 12 vertically HIV-infected patients included in the study
| With M184V in pDNA |
Without M184V in pDNA |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P1 | P2 | P3 | P4 | P5 | P6 | P7 | P8 | P9 | P10 | P11 | P12 | P value | |
| Timepoint PBMCs | |||||||||||||
| Time on ART | 17.2 | 14.3 | 12.4 | 9.8 | 18.8 | 14.7 | 8.8 | 13.7 | 13.8 | 17.9 | 13.5 | 10.8 | 0.7 |
| Time from point 1 | 11 | 5.1 | 1.5 | 8.8 | 7.6 | 1.8 | 8.3 | 13.4 | 2.9 | 12.1 | 6.6 | 10.8 | 0.5 |
| Time with undetectable VL since point 1 | 10.2 | 5.1 | 1.5 | 6.2 | 7.5 | 1.8 | 2.1 | 3 | 1.9 | 3.6 | 4.4 | 9 | 0.9 |
| Total time with 3TC/FTC exposure | 6.6 | 6.9 | 7.5 | 1.1 | 15 | 6.8 | 5.9 | 6.7 | 12.9 | 10.2 | 12 | 10.8 | 0.6 |
| Time with 3TC/FTC exposure before point 1 | 6.2 | 1.8 | 6.1 | 1.1 | 7.4 | 5.1 | 2.4 | 2.3 | 10.7 | 1.8 | 5.8 | 0 | 0.6 |
| Time with 3TC/FTC exposure since point 1 | 0.4 | 5.1 | 1.4 | 0 | 7.6 | 1.7 | 3.5 | 4.4 | 2.2 | 8.4 | 6.2 | 10.8 | 0.3 |
| ART regimen | RPV/DTG | FTC/TDF/ EFV | FTC/TDF/ EFV | ZDV/ABC/ LPV/r | FTC/TDF/ DRV/r | FTC/TDF/ DRV/r | 3TC/ABC/ ATV/r | FTC/TDF/ DRV/r | 3TC/ABC/ EFV | DRV/r | FTC/TDF/ LPV/r | 3TC/ABC EFV | – |
| Duration ART regimen | 3.5 | 2.5 | 1.1 | 3.7 | 3.8 | 1.7 | 3.6 | 3.1 | 2.1 | 2.8 | 4.6 | 1.2 | 0.4 |
| 31 December 2019 | |||||||||||||
| Time from PBMC sampling | 1.2 | 8.5 | 9.2 | 7.5 | 5 | 8.2 | 8.8 | 6.5 | 6.8 | 6.7 | 9.2 | 1.7 | 0.7 |
| ART regimen | RPV/DTG | FTC/TAF/ RPV | FTC/TAF/ RPV | 3TC/ABC/ DTG | 3TC/ABC/ DTG | 3TC/ABC/ DTG | 3TC/ABC/ DTG | 3TC/ABC/ DTG | 3TC/DRV/c | DRV/c | DRV/r DTG | 3TC/ABC/ EFV | – |
All times and ages are expressed in years. Point 1 refers to collection time of historic plasma carrying M184V. Timepoint PBMCs refers to PBMCs sampling time. 31 December 2019, last evaluation; total time 3TC/FTC exposure refers to cumulative exposure to 3TC/FTC. P, patient; ART, antiretroviral therapy. VL, viral load (RNA-HIV-1 copies/mL); pDNA, proviral DNA. 3TC, lamivudine; FTC, emtricitabine; ABC, abacavir; RPV, rilpivirine; TDF, tenofovir disoproxil fumarate; TAF, tenofovir alafenamide; EFV, efavirenz; ZDV, zidovudine; LPV/r, lopinavir/ritonavir; DRV/r, darunavir/ritonavir; ATV/r, atazanavir/ritonavir; DRV/c, darunavir/cobicistat; DTG, dolutegravir.